| Terminated | Metformin+Cytarabine for the Treatment of Relapsed/Refractory AML NCT01849276 | Northwestern University | Phase 1 |
| Terminated | MEK Inhibitor MEK162, Idarubicin, and Cytarabine in Treating Patients With Relapsed or Refractory Acute Myeloi NCT02049801 | Bruno C. Medeiros | Phase 1 |
| Unknown | Eltrombopag Olamine in Improving Platelet Recovery in Older Patients With Acute Myeloid Leukemia Undergoing Ch NCT02071901 | Case Comprehensive Cancer Center | Phase 2 |
| Terminated | Omacetaxine Mepesuccinate, Cytarabine, and Decitabine in Treating Older Patients With Newly Diagnosed Acute My NCT02029417 | Roswell Park Cancer Institute | Phase 2 |
| Terminated | Ixazomib (MLN9708) in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia NCT02030405 | Steven E. Coutre | Phase 2 |
| Terminated | AML Therapy With Irradiated Allogeneic Cells NCT02105116 | Rutgers, The State University of New Jersey | N/A |
| Terminated | Lenalidomide and Combination Chemotherapy in Treating Patients With Relapsed or Refractory Acute Myeloid Leuke NCT01904643 | Stanford University | Phase 1 |
| Completed | Treatment for Relapsed/Refractory AML Based on a High Throughput Drug Sensitivity Assay NCT01872819 | University of Washington | N/A |
| Withdrawn | Arsenic Trioxide in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia NCT01835288 | Stanford University | Phase 2 |
| Completed | Idarubicin, Cytarabine, and Pravastatin Sodium in Treating Patients With Acute Myeloid Leukemia or Myelodyspla NCT01831232 | Fred Hutchinson Cancer Center | N/A |
| Completed | Lithium Carbonate and Tretinoin in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia NCT01820624 | Paolo Caimi, MD | Phase 1 |
| Completed | Sirolimus, Idarubicin, and Cytarabine in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia NCT01822015 | Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University | EARLY_Phase 1 |
| Terminated | Donor Stem Cell Transplant in Treating Patients With High Risk Acute Myeloid Leukemia NCT01801046 | University of Southern California | Phase 1 |
| Terminated | Decitabine Followed by Idarubicin and Cytarabine in Treating Patients With Relapsed or Refractory AML and MDS NCT01607645 | Fred Hutchinson Cancer Center | Phase 2 |
| Completed | Azacitidine, Cytarabine, and Mitoxantrone Hydrochloride in Treating Patients With High-Risk Acute Myeloid Leuk NCT01839240 | University of Chicago | Phase 1 |
| Terminated | Eltrombopag Olamine in Treating Patients With Relapsed/Refractory Acute Myeloid Leukemia NCT01550185 | Roswell Park Cancer Institute | Phase 1 |
| Terminated | Cholecalciferol in Treating Patients With Acute Myeloid Leukemia Undergoing Intensive Induction Chemotherapy NCT01521936 | Roswell Park Cancer Institute | Phase 2 |
| Completed | Trebananib With or Without Low-Dose Cytarabine in Treating Patients With Acute Myeloid Leukemia NCT01555268 | Roswell Park Cancer Institute | Phase 1 |
| Completed | Alvocidib, Cytarabine, and Mitoxantrone Hydrochloride or Cytarabine and Daunorubicin Hydrochloride in Treating NCT01349972 | National Cancer Institute (NCI) | Phase 2 |
| Terminated | Cyclosporine, Pravastatin Sodium, Etoposide, and Mitoxantrone Hydrochloride in Treating Patients With Relapsed NCT01342887 | Fred Hutchinson Cancer Center | Phase 1 / Phase 2 |
| Completed | Clofarabine or Daunorubicin Hydrochloride and Cytarabine Followed By Decitabine or Observation in Treating Old NCT02085408 | ECOG-ACRIN Cancer Research Group | Phase 3 |
| Completed | Early Discharge and Outpatients Care in Patients With Myelodysplastic Syndrome or Acute Myeloid Leukemia Previ NCT01235572 | Fred Hutchinson Cancer Center | Phase 2 |
| Completed | AKT Inhibitor MK-2206 in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia NCT01253447 | National Cancer Institute (NCI) | Phase 2 |
| Completed | Bortezomib, Mitoxantrone, Etoposide, and Cytarabine in Relapsed or Refractory Acute Myeloid Leukemia NCT01127009 | Case Comprehensive Cancer Center | Phase 1 |
| Terminated | Entinostat and Sorafenib Tosylate in Treating Patients With Advanced or Metastatic Solid Tumors or Refractory NCT01159301 | National Cancer Institute (NCI) | Phase 1 |
| Completed | Clofarabine, Cytarabine, and Filgrastim Followed by Infusion of Non-HLA Matched Ex Vivo Expanded Cord Blood Pr NCT01031368 | Nohla Therapeutics, Inc. | Phase 1 |
| Completed | Vorinostat, Azacitidine, and Gemtuzumab Ozogamicin for Older Patients With Relapsed or Refractory AML NCT00895934 | National Cancer Institute (NCI) | Phase 1 / Phase 2 |
| Completed | Choline Magnesium Trisalicylate and Combination Chemotherapy in Treating Patients With Acute Myeloid Leukemia NCT02144675 | Rutgers, The State University of New Jersey | Phase 2 |
| Completed | Alvocidib, Cytarabine, and Mitoxantrone in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia NCT00795002 | National Cancer Institute (NCI) | Phase 2 |
| Completed | Comparing Three Different Combination Chemotherapy Regimens in Treating Patients With Relapsed or Refractory A NCT00634244 | National Cancer Institute (NCI) | Phase 2 |
| Completed | Bortezomib, Daunorubicin, and Cytarabine in Treating Older Patients With Previously Untreated Acute Myeloid Le NCT00742625 | National Cancer Institute (NCI) | Phase 1 / Phase 2 |
| Completed | Bortezomib and Combination Chemotherapy in Treating Younger Patients With Recurrent, Refractory, or Secondary NCT00666588 | National Cancer Institute (NCI) | Phase 2 |
| Terminated | Vorinostat and Gemtuzumab Ozogamicin in Treating Older Patients With Previously Untreated Acute Myeloid Leukem NCT00673153 | Fred Hutchinson Cancer Center | Phase 2 |
| Completed | Tipifarnib and Etoposide in Treating Older Patients With Newly Diagnosed, Previously Untreated Acute Myeloid L NCT00602771 | National Cancer Institute (NCI) | Phase 2 |
| Completed | Donor Umbilical Cord Blood Stem Cell Transplant in Treating Patients With Hematologic Malignancies NCT01093586 | Case Comprehensive Cancer Center | Phase 2 |
| Completed | Flavopiridol, Cytarabine, and Mitoxantrone in Treating Patients With Relapsed or Refractory Acute Leukemia NCT00470197 | National Cancer Institute (NCI) | Phase 1 |
| Completed | MS-275 and GM-CSF in Treating Patients With Myelodysplastic Syndrome and/or Relapsed or Refractory Acute Myelo NCT00462605 | National Cancer Institute (NCI) | Phase 2 |
| Completed | Alvocidib, Cytarabine, and Mitoxantrone in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia NCT00407966 | National Cancer Institute (NCI) | Phase 2 |
| Completed | Lenalidomide in Treating Older Patients With Acute Myeloid Leukemia NCT00352365 | National Cancer Institute (NCI) | Phase 2 |
| Completed | Vorinostat, Cytarabine, and Etoposide in Treating Patients With Relapsed and/or Refractory Acute Leukemia or M NCT00357305 | National Cancer Institute (NCI) | Phase 1 |
| Completed | Vorinostat in Treating Patients With Acute Myeloid Leukemia NCT00305773 | National Cancer Institute (NCI) | Phase 2 |
| Completed | 7-Hydroxystaurosporine and Perifosine in Treating Patients With Relapsed or Refractory Acute Leukemia, Chronic NCT00301938 | National Cancer Institute (NCI) | Phase 1 |
| Terminated | 17-N-Allylamino-17-Demethoxygeldanamycin and Bortezomib in Treating Patients With Relapsed or Refractory Hemat NCT00103272 | National Cancer Institute (NCI) | Phase 1 |
| Completed | Tipifarnib and Etoposide in Treating Older Patients With Newly Diagnosed Acute Myeloid Leukemia NCT00112853 | National Cancer Institute (NCI) | Phase 1 |
| Completed | SB-715992 in Treating Patients With Acute Leukemia, Chronic Myelogenous Leukemia, or Advanced Myelodysplastic NCT00098826 | National Cancer Institute (NCI) | Phase 1 |
| Completed | Tanespimycin and Cytarabine in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia, Acute Lym NCT00098423 | National Cancer Institute (NCI) | Phase 1 |
| Completed | Tipifarnib in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia NCT00101296 | National Cancer Institute (NCI) | Phase 1 |
| Completed | XK469R in Treating Patients With Refractory Hematologic Cancer NCT00095797 | National Cancer Institute (NCI) | Phase 1 |
| Terminated | Idarubicin and Cytarabine With or Without Bevacizumab in Treating Patients With Newly Diagnosed Acute Myeloid NCT00096148 | National Cancer Institute (NCI) | Phase 2 |
| Terminated | Flavopiridol in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia, Acute Lymphoblastic Leuk NCT00101231 | National Cancer Institute (NCI) | Phase 1 |
| Completed | Idarubicin, Cytarabine, and Tipifarnib in Treating Patients With Newly Diagnosed Myelodysplastic Syndromes or NCT00096122 | National Cancer Institute (NCI) | Phase 1 / Phase 2 |
| Completed | S0432 Tipifarnib in Treating Older Patients With Acute Myeloid Leukemia NCT00093418 | National Cancer Institute (NCI) | Phase 2 |
| Terminated | Cilengitide in Treating Patients With Acute Myeloid Leukemia NCT00089388 | National Cancer Institute (NCI) | Phase 2 |
| Completed | Reduced Intensity Donor Peripheral Blood Stem Cell Transplant in Treating Patients With De Novo or Secondary A NCT00045435 | Fred Hutchinson Cancer Center | Phase 2 |
| Completed | Tipifarnib in Treating Older Patients With Previously Untreated Acute Myeloid Leukemia NCT00027872 | National Cancer Institute (NCI) | Phase 2 |
| Completed | Combination Chemotherapy With or Without PSC 833, Peripheral Stem Cell Transplantation, and/or Interleukin-2 i NCT00006363 | National Cancer Institute (NCI) | Phase 3 |
| Completed | Combination Chemotherapy With or Without Valspodar in Treating Patients With Previously Untreated Acute Myeloi NCT00003190 | National Cancer Institute (NCI) | Phase 3 |
| Completed | High-Dose Busulfan and High-Dose Cyclophosphamide Followed By Donor Bone Marrow Transplant in Treating Patient NCT01177371 | Case Comprehensive Cancer Center | Phase 2 |